Bristol-Myers Squibb(US:BMY) Investor Placeยท2024-07-31 11:00Core Viewpoint - The aging U.S. population is a significant driver for the healthcare sector, leading to increased demand for specific healthcare companies that cater to the elderly [1] Group 1: Bristol Myers-Squibb (BMY) - In 2021, the U.S. Medicare program spent $216 billion on subsidized prescriptions for seniors, with BMY receiving $12.6 billion for its blood-thinning drug Eliquis, accounting for over 25% of its $46 billion revenue [2] - The demand for blood thinners is expected to rise as more individuals enter the age bracket where such medications are necessary [2] - Medicare also paid $5.9 billion for BMY's Revlimid, a treatment for multiple myeloma, which is prevalent among seniors [2][3] Group 2: Eli Lilly (LLY) - Eli Lilly's Mounjaro, a weight loss drug, and its Trulicity diabetes drug, which generated $4.7 billion in Part D-covered prescriptions, position the company for long-term success [4] - Eli Lilly has negotiated new pricing with the federal government for its drugs, effective in 2026, which may enhance its sales potential [5] Group 3: Tenet Healthcare (THC) - Tenet Healthcare operates a large and diversified healthcare service network, including over 535 ambulatory surgery centers and 52 hospitals [6] - THC has experienced over 100% share value growth year-to-date and is projected to reach a valuation of $200 per share with continued performance [6][7] - The company is expected to grow as it acquires more facilities to meet the demands of the aging U.S. population [7]